| Tag | Content |
|---|---|
| UniProt Accession | SOCS1_HUMAN; O15524; |
| Entrez ID | 8651 |
| GenBank Protein ID | |
| GenBank Nucleotide ID | |
| Protein Name | Suppressor of cytokine signaling 1 (SOCS-1) (JAK-binding protein) (JAB) (STAT-induced STAT inhibitor 1) (SSI-1) (Tec-interacting protein 3) (TIP-3) |
| Gene Name | SOCS1; SSI1; TIP3 |
| Organism | Homo sapiens |
| NCBI Taxa ID | 9606 |
| Functional Description | SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS1 is involved in negative regulation of cytokines that signal through the JAK/STAT3 pathway. Through binding to JAKs, inhibits their kinase activity. In vitro, also suppresses Tec protein-tyrosine activity. Appears to be a major regulator of signaling by interleukin 6 (IL6) and leukemia inhibitory factor (LIF). Regulates interferon-gamma mediated sensory neuron survival (By similarity). Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize JAK2. SOCS1 appears to be a negative regulator in IGF1R signaling pathway. |
| Sequence (Fasta) | MVAHNQVAAD NAVSTAAEPR RRPEPSSSSS SSPAAPARPR PCPAVPAPAP GDTHFRTFRS 60 HADYRRITRA SALLDACGFY WGPLSVHGAH ERLRAEPVGT FLVRDSRQRN CFFALSVKMA 120 SGPTSIRVHF QAGRFHLDGS RESFDCLFEL LEHYVAAPRR MLGAPLRQRR VRPLQELCRQ 180 RIVATVGREN LARIPLNPVL RDYLSSFPFQ I 212 |
|
||||||||||||||||||||||||||||||||||||||||||||||
| Database | Annotation |
|---|---|
| Cancer Gene Census | Hodgkin lymphoma, PMBL |
| CTD (Curated) (count: 5) | MESH:D017449
; Dermatitis, Allergic Contact MESH:D008106 ; Liver Cirrhosis, Experimental MESH:D008107 ; Liver Diseases MESH:D008114 ; Liver Neoplasms, Experimental MESH:D015427 ; Reperfusion Injury |
| HGMD (count: 1) | CD073702; Adult asthma, association with; Small deletions
|
| GWASdb (count: 1) | rs188754154; Primary biliary cirrhosis; primary biliary cirrhosis |
| PTM | Modification Sites |
|---|---|
| Network | Interaction | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | Source | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||